Clinical Trials Logo

Penile Induration clinical trials

View clinical trials related to Penile Induration.

Filter by:
  • Active, not recruiting  
  • Page 1

NCT ID: NCT05871177 Active, not recruiting - Peyronie Disease Clinical Trials

Safety and Efficacy of Intralesional HiLow Hyaluronic Acid in the Treatment of Peyronie's Disease (PD)

Start date: May 5, 2023
Phase: N/A
Study type: Interventional

Prospective, open-label, single-arm, multicentric, pilot clinical study to confirm the safety of HiLow hyaluronic acid sodium salt for intralesional penile injection in patients affected by PD.

NCT ID: NCT05480683 Active, not recruiting - Peyronie Disease Clinical Trials

Pelvic CT With Agatston Calcium Score for Peyronie Disease

Start date: August 4, 2022
Phase: N/A
Study type: Interventional

The purpose of this study is to find out how including a CT exam of the penis can help urologists make treatment decisions for patients with calcified Peyronie's disease.

NCT ID: NCT04786106 Active, not recruiting - Peyronie's Disease Clinical Trials

Investigation of Surgery, Collagenase, and Restorex for the Improvement of Peyronie's

iSCRIP
Start date: December 30, 2020
Phase: Phase 4
Study type: Interventional

The purpose of this study is to compare key clinical outcomes of collagenase clostridium histolyticum injections versus surgery for the management of Peyronie's Disease.

NCT ID: NCT04771442 Active, not recruiting - Penile Diseases Clinical Trials

Stem Cell Treatment of Peyronie´s Disease.

Start date: September 9, 2022
Phase: Phase 1
Study type: Interventional

Purpose of the project is to investigate if a single injection of autologous stromal vascular fraction into and around plaque is a safe and suitable treatment. Twentythree men > 18 years with Peyronie´s Disease in the chronic phase will be recruited. The operative same-day procedure will be performed in general anaesthesia by a plastic surgeon. Before the patient wake, local anaesthesia is put around the penis. Processed stem cells are injected into the plaque/fibrosis subcutaneously. There will be a follow up at 1, 3, 6, 12 months. It is a pilot study with no randomisation. The group will be compared to a historical control group.